Clinical trial · Observational
Retrospective, Observational, Multi-center Study Evaluating the Efficacy and Tolerance of Brigatinib in the Management of Rearranged CBNPC ROS1
NCT04718012CI-TRIAL-00055176BRIGAROScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
ROS1 translocated Non small cell lung cancer (NSCLC) is a rare type of lung cancer with few datas. We collected datas concerning patients with ROS1 translocated NSCLC who received Brigatinib in the Compassionate Access after two others Tyrosine kinase Inhibitors
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer ROS Translocated | Lung Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- progression-free survival on Brigatinib in patients with ROS1 translocated CBNPCtransloated CBNPC
- timeFrame
- 27 months
Secondary outcomes (3)
- measure
- overall survival
- timeFrame
- 27 months
- measure
- Number of side effects associated with brigatinib
- timeFrame
- 27 months
- measure
- Types of side efects associated with brigatinib
- timeFrame
- 27 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patient with CBNPC transloated ROS1 * Treatment by Brigatinib as part of compassionate access in France * Patient \> 18 years old Exclusion Criteria: * Refusal of the patient to participate in this study
References
Publications (0)
Data not yet available
No reference posted for this study.